Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

Detalles Bibliográficos
Autor principal: O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239505/
https://www.ncbi.nlm.nih.gov/pubmed/32436148
http://dx.doi.org/10.1007/s10549-020-05674-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239505/
https://www.ncbi.nlm.nih.gov/pubmed/32436148
http://dx.doi.org/10.1007/s10549-020-05674-7

Ejemplares similares